Bryan Johnson Considers Selling Blueprint
Analysis based on 7 articles · First reported Jul 22, 2025 · Last updated Jul 23, 2025
The potential closure or sale of Blueprint could impact the wellness and biotech industries, particularly in the anti-aging segment. Investors in similar private companies might reassess their positions given the challenges faced by Blueprint and its founder's shifting priorities.
Bryan Johnson, the 47-year-old biotech entrepreneur and founder of Blueprint, is considering shutting down or selling his anti-aging startup. Johnson, known for his 'Project Blueprint' anti-aging regimen, stated that the company has become a 'pain-in-the-ass' and is interfering with his focus on his newly founded religion, 'Don't Die.' While Johnson claims Blueprint is at break-even, The New York Times previously reported the company was missing its break-even point by at least $1 million a month. Johnson's decision highlights a pivot from commercial ventures to philosophical pursuits, impacting the future of Blueprint and its wellness products.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard